Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03337152
Other study ID # 856370-2
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date May 7, 2018
Est. completion date October 21, 2018

Study information

Verified date May 2019
Source PATH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A clinical study designed to develop and inform an individual risk of hemolysis model based on individual red blood cell G6PD levels. Volunteers who are eligible to treatment with primaquine as per national guidelines and with confirmed normal G6PD levels as per the fluorescent spot test will be exposed to treatment regimens of either primaquine alone for 14 days or 3 day chloroquine with concomitant primaquine for 14 days. The volunteers will be followed intensively during treatment and for 14 days after treatment for haematologic measures, G6PD quantification, and drug level assays.


Description:

Open label, randomized trial with 72 total participants assigned to one of two treatment arms. Each arm will have 36 participants comprised of 12 males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD with a normal fluorescent spot test (FST) (G6PD genotype abnormal with G6PD activity ≥40% and ≤80% of normal). Arm 1a will receive primaquine for 14 days, and Arm 1b will receive chloroquine for 3 days and concomitant primaquine for 14 days. All participants will be healthy volunteers without severe G6PD deficiency who will be followed for two weeks after completing their study drug dosing. Pregnant women and those breastfeeding will be excluded. Venous blood samples will be taken at regular intervals for haematologic measures, G6PD quantification, and drug level assays. G6PD levels will be measured both by spectrophotometry to provide whole blood G6PD levels normalized for hemoglobin, as well by flow cytometry to to provide red blood cell G6PD distributions throughout the treatment and post treatment. Changes in the G6PD distributions will be modeled, incorporating other critical haematological indicators collected throughout the study too.


Recruitment information / eligibility

Status Terminated
Enrollment 54
Est. completion date October 21, 2018
Est. primary completion date August 21, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Previous G6PD test at Shoklo Malaria Research Unit (SMRU) clinic with one of following results: 1) G6PD homozygous wildtype females (G6PD genotype normal) 2) G6PD heterozygous females with a normal FST (G6PD genotype abnormal with G6PD activity =40% and =80% of normal ) 3) G6PD hemizygous wildtype males (G6PD genotype normal) - Willing to participate and sign informed consent form - Willing to allow donated samples to be used in future research - Aged =18 years - Ability (in the investigators' opinion) and willing to comply with all study requirements Exclusion Criteria: All participants: - Malaria or other illness - Recent history (within 20 days) of anti-malarial treatment - History of allergy or adverse reaction to chloroquine or primaquine - Blood transfusion in the past 3 months - G6PD activity less than 40% normal activity or 3.00 IU/gHb by the quantitative G6PD spectrophotometric assay - Haemoglobin =10 g/dL - Presence of any condition which in the judgment of the investigator would place the subject at undue risk or interfere with the results of the study Female participants only: - Pregnancy at the time of screening - Breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
primaquine
Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
chloroquine + primaquine
Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.

Locations

Country Name City State
Thailand Shoklo Malaria Research Unit (SMRU) Mae Sot

Sponsors (2)

Lead Sponsor Collaborator
PATH Mahidol Oxford Tropical Medicine Research Unit

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Haemoglobin The change in haemoglobin from baseline on exposure to primaquine for P.vivax treatment over treatment course to hemoglobin level at day 28. 28 days after enrollment
Primary Change in G6PD Concentration The haemoglobin-related change in G6PD concentration, as determined by spectrometer, over treatment course.
Change is determined from baseline to day 28
28 days after enrollment
Secondary Significance of CYP2D6 relevance of Dextromethorphan assay results to risk of haemolysis models 28 days after enrollment
Secondary Association of Drug Levels Association of chloroquine and primaquine drug levels at the time of sampling for haematological and G6PD profiles. Days 1,2,3,5,7,9,11,14,17,21
Secondary Serious Adverse Events frequency of serious adverse events in women heterozygous for G6PD 28 days after enrollment
Secondary Significance of Reticulocyte Count relevance of reticulocyte count to risk of haemolysis models Days 1,2,3,5,7,9,11,14,17,21
Secondary Significance of Urobilinogen Levels relevance of urobilinogen tests to risk of haemolysis models Days 1,2,3,5,7,9,11,14,17,21
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05096702 - Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
Recruiting NCT05540470 - Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield N/A
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT03307369 - A Retrospective Study of Severe Plasmodium Vivax
Completed NCT01213966 - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection Phase 2
Completed NCT00811096 - Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax Phase 2
Completed NCT05753150 - Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
Completed NCT02751294 - A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution Phase 1
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Completed NCT03377296 - Study of Controlled Human Plasmodium Vivax Infection N/A
Completed NCT00486694 - Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria Phase 2
Recruiting NCT05788094 - ACT vs CQ With Tafenoquine for P. Vivax Mono-infection Phase 4
Terminated NCT02110784 - Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Phase 2
Not yet recruiting NCT05690841 - FocaL Mass Drug Administration for Vivax Malaria Elimination Phase 3
Not yet recruiting NCT04739917 - Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers Phase 2
Completed NCT03208907 - DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil Phase 3
Completed NCT02184637 - A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate Phase 1
Completed NCT01928914 - Tafenoquine Thorough QTc Study in Healthy Subjects Phase 1
Completed NCT00157885 - A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia. N/A
Completed NCT01081847 - Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants Phase 1